these four are signficant players in the genome sequencing market, but RHHB stock price hasn't take off in the same way, and Agilent is way out in front.
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
Pernyataan Penyangkalan
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Pernyataan Penyangkalan
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.